Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Harley-Davidson Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.68 (market cap $39.89B), while Harley-Davidson Inc trades at $25.79 (market cap $2.65B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HOG | |
|---|---|---|
Market Cap | $39.89B | $2.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $31.03 |
52-Week Low | $278.09 | $17.19 |
Enterprise Value | $38.15B | $3.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Harley-Davidson (HOG) trades at $25.14, up 1.17% today, with a neutral technical outlook and mixed earnings history. The company reported Q1 2026 EPS of $0.22, missing estimates, but Q2 2026 results are due July 23, 2026. Recent news highlights production shifts back to the U.S. and cost-cutting initiatives. Valuation ratios appear attractive with a P/E of 13.03 and P/B of 0.86, though revenue has declined from $5.8B in 2023 to $4.5B in 2025.
The stock faces headwinds from declining revenue and margin pressure, but cost reductions and strategic shifts under new CEO Artie Starrs offer turnaround potential. Analyst consensus is cautious with a $23.20 price target below current levels. Key risks include competitive pressures and execution challenges. The upcoming Q2 earnings will be critical for confirming demand recovery and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
